vs
Side-by-side financial comparison of CF BANKSHARES INC. (CFBK) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
CF BANKSHARES INC. is the larger business by last-quarter revenue ($15.7M vs $9.3M, roughly 1.7× STRATA Skin Sciences, Inc.). CF BANKSHARES INC. runs the higher net margin — 40.0% vs 0.6%, a 39.4% gap on every dollar of revenue. On growth, CF BANKSHARES INC. posted the faster year-over-year revenue change (12.6% vs -3.0%). CF BANKSHARES INC. produced more free cash flow last quarter ($18.2M vs $-551.0K). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs 13.7%).
CF Bankshares Inc. is a U.S.-based regional bank holding company operating through its community bank subsidiary. It offers a full suite of personal and commercial banking solutions including deposit products, various loan options, wealth management services and digital banking tools, primarily serving individual consumers and small-to-medium business clients across the U.S. Midwest region.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
CFBK vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.7M | $9.3M |
| Net Profit | $5.7M | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | 43.4% | 5.3% |
| Net Margin | 40.0% | 0.6% |
| Revenue YoY | 12.6% | -3.0% |
| Net Profit YoY | 29.9% | 101.3% |
| EPS (diluted) | $0.88 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.7M | $9.3M | ||
| Q3 25 | $15.5M | $6.9M | ||
| Q2 25 | $15.6M | $7.7M | ||
| Q1 25 | $14.1M | $6.8M | ||
| Q4 24 | $14.0M | $9.6M | ||
| Q3 24 | $13.1M | $8.8M | ||
| Q2 24 | $12.6M | $8.4M | ||
| Q1 24 | $12.2M | $6.8M |
| Q4 25 | $5.7M | $58.0K | ||
| Q3 25 | $2.3M | $-1.6M | ||
| Q2 25 | $5.0M | $-2.6M | ||
| Q1 25 | $4.4M | $-2.1M | ||
| Q4 24 | $4.4M | $-4.6M | ||
| Q3 24 | $4.2M | $-2.1M | ||
| Q2 24 | $1.7M | $-91.0K | ||
| Q1 24 | $3.1M | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | 43.4% | 5.3% | ||
| Q3 25 | 17.5% | -16.9% | ||
| Q2 25 | 41.1% | -30.1% | ||
| Q1 25 | 39.5% | -25.0% | ||
| Q4 24 | 36.9% | -44.7% | ||
| Q3 24 | 40.4% | -18.2% | ||
| Q2 24 | 15.4% | -5.7% | ||
| Q1 24 | 30.9% | -42.7% |
| Q4 25 | 40.0% | 0.6% | ||
| Q3 25 | 15.1% | -23.4% | ||
| Q2 25 | 32.3% | -33.6% | ||
| Q1 25 | 31.4% | -31.2% | ||
| Q4 24 | 35.2% | -47.6% | ||
| Q3 24 | 32.2% | -23.6% | ||
| Q2 24 | 13.5% | -1.1% | ||
| Q1 24 | 25.2% | -49.8% |
| Q4 25 | $0.88 | $0.14 | ||
| Q3 25 | $0.36 | $-0.36 | ||
| Q2 25 | $0.77 | $-0.62 | ||
| Q1 25 | $0.68 | $-0.51 | ||
| Q4 24 | $0.68 | $-2.01 | ||
| Q3 24 | $0.65 | $-0.51 | ||
| Q2 24 | $0.26 | $-0.03 | ||
| Q1 24 | $0.47 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $184.4M | $2.9M |
| Total Assets | $2.1B | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $259.0M | $7.9M | ||
| Q3 25 | $272.4M | $7.1M | ||
| Q2 25 | $275.7M | $6.0M | ||
| Q1 25 | $241.0M | $6.5M | ||
| Q4 24 | $235.3M | $7.3M | ||
| Q3 24 | $233.5M | $7.1M | ||
| Q2 24 | $241.8M | $5.5M | ||
| Q1 24 | $236.9M | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $184.4M | $2.9M | ||
| Q3 25 | $179.3M | $1.3M | ||
| Q2 25 | $177.0M | $532.0K | ||
| Q1 25 | $172.7M | $3.0M | ||
| Q4 24 | $168.4M | $5.0M | ||
| Q3 24 | $164.0M | $9.4M | ||
| Q2 24 | $159.6M | $9.5M | ||
| Q1 24 | $158.0M | $9.4M |
| Q4 25 | $2.1B | $30.5M | ||
| Q3 25 | $2.1B | $30.7M | ||
| Q2 25 | $2.1B | $29.5M | ||
| Q1 25 | $2.1B | $33.0M | ||
| Q4 24 | $2.1B | $34.9M | ||
| Q3 24 | $2.1B | $39.4M | ||
| Q2 24 | $2.0B | $38.8M | ||
| Q1 24 | $2.0B | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.7M | $-239.0K |
| Free Cash FlowOCF − Capex | $18.2M | $-551.0K |
| FCF MarginFCF / Revenue | 115.6% | -5.9% |
| Capex IntensityCapex / Revenue | 3.1% | 3.4% |
| Cash ConversionOCF / Net Profit | 3.26× | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $33.4M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.7M | $-239.0K | ||
| Q3 25 | $5.5M | $-64.0K | ||
| Q2 25 | $8.0M | $-1.9M | ||
| Q1 25 | $2.2M | $-550.0K | ||
| Q4 24 | $14.2M | $703.0K | ||
| Q3 24 | $-1.3M | $-302.0K | ||
| Q2 24 | $4.0M | $591.0K | ||
| Q1 24 | $-1.2M | $-804.0K |
| Q4 25 | $18.2M | $-551.0K | ||
| Q3 25 | $5.2M | $-1.1M | ||
| Q2 25 | $7.8M | $-2.0M | ||
| Q1 25 | $2.2M | $-749.0K | ||
| Q4 24 | $13.9M | $199.0K | ||
| Q3 24 | $-1.3M | $-364.0K | ||
| Q2 24 | $4.0M | $246.0K | ||
| Q1 24 | $-1.2M | $-1.5M |
| Q4 25 | 115.6% | -5.9% | ||
| Q3 25 | 33.6% | -15.6% | ||
| Q2 25 | 50.3% | -26.1% | ||
| Q1 25 | 15.2% | -11.0% | ||
| Q4 24 | 99.6% | 2.1% | ||
| Q3 24 | -9.9% | -4.1% | ||
| Q2 24 | 31.6% | 2.9% | ||
| Q1 24 | -9.5% | -22.6% |
| Q4 25 | 3.1% | 3.4% | ||
| Q3 25 | 1.7% | 14.7% | ||
| Q2 25 | 0.7% | 0.8% | ||
| Q1 25 | 0.4% | 2.9% | ||
| Q4 24 | 1.9% | 5.3% | ||
| Q3 24 | 0.2% | 0.7% | ||
| Q2 24 | 0.1% | 4.1% | ||
| Q1 24 | 0.0% | 10.7% |
| Q4 25 | 3.26× | -4.12× | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 3.21× | — | ||
| Q3 24 | -0.30× | — | ||
| Q2 24 | 2.35× | — | ||
| Q1 24 | -0.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CFBK
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
